REGN5093-M114
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig and the tubulin-inhibiting linker-payload (HY-148528).
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; c-Met/HGFR; Microtubule/Tubulin
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
[REGN5093-M114]
References & Citations
[1]Dardare J, et al., REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer? Transl Lung Cancer Res. 2024 Aug 31;13 (8) :2082-2086.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0062005 3x 1.0 µg
AIC sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Sign In for Pricing
View Details 